Articles related to BLADDER CANCER

Workplace exposure to harmful chemicals remains a significant risk factor for bladder cancer, particularly affecting specific occupations and requiring targeted prevention strategies.

In cisplatin-eligible patients with muscle-invasive bladder cancer, perioperative durvalumab combined with standard chemotherapy demonstrated an 8% absolute improvement in event-free survival at 24 months compared to chemotherapy alone.

The TROPiCs-04 trial results challenge the current treatment landscape for metastatic urothelial carcinoma, highlighting the need for new strategies post-relapse and the importance of next-generation sequencing in patient selection.

This pivotal study demonstrates that the combination of enfortumab vedotin and pembrolizumab not only extends progression-free survival but also significantly improves overall survival rates in patients with untreated advanced urothelial carcinoma.

This study illuminates the potential of preoperative circulating tumor DNA to redefine the approach to treating high-risk upper tract urothelial carcinoma, offering a nuanced tool for assessing the necessity of neoadjuvant chemotherapy and tailoring patient care.

ESMO Congress 2023 unveils groundbreaking advances in mUC treatments, emphasizing novel therapeutic combinations and the critical role of personalized medicine in improving patient outcomes.